Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
Open Access
- 4 February 2011
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 28 (2) , 110-125
Abstract
Respiratory syncytial virus (RSV) causes significant morbidity in very young children, preterm infants with and without chronic lung disease, and children with hemodynamically significant congenital heart disease. In the absence of a safe and effective vaccine, alternative means of protecting high-risk infants and young children from serious RSV illness have been studied. Clinical observations and animal model data over the past 30 years suggested that RSV immunoglobulin G (IgG) neutralizing antibodies might offer protection from severe RSV lower respiratory tract disease. Transfer of adequate amounts of IgG to the fetus does not occur efficiently until the third trimester of pregnancy, which helps to explain why premature infants are at high risk of serious RSV illness. Efforts shifted toward the prophylactic monthly administration of standard immunoglobulins and, later, of RSV-enriched immunoglobulin in selected high-risk infants and young children. Although this approach proved effective, RSV-enriched immune globulin was not suitable for all patients and administration was labor intensive. The development of palivizumab, a monoclonal antibody that can bind to a specific antigenic site on the virus and prevent cell-to-cell spread of infection has since become the mainstay of RSV illness prevention in preterm infants and those with significant congenital heart disease. Palivizumab, the only monoclonal antibody approved for the prevention of RSV lower respiratory tract disease must be administered monthly throughout the RSV season and does not always prevent serious RSV illness. Further research to develop more effective and less labor-intensive immunoprophylactic agents is ongoing.Keywords
This publication has 48 references indexed in Scilit:
- Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit FusionJournal of Virology, 2010
- Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority TrialPediatrics, 2010
- Persistent activation of an innate immune response translates respiratory viral infection into chronic lung diseaseNature Medicine, 2008
- Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care UnitPediatrics, 2004
- Prophylaxis with Respiratory Syncytial Virus F–Specific Humanized Monoclonal Antibody Delays and Moderately Suppresses the Native Antibody Response but Does Not Impair Immunity to Late RechallengeThe Journal of Infectious Diseases, 1999
- Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseThe Journal of Pediatrics, 1998
- Comparison of Antibody Concentrations and Protective Activity of Respiratory Syncytial Virus Immune Globulin and Conventional Immune GlobulinThe Journal of Infectious Diseases, 1994
- Relation of Serum Antibody to Glycoproteins of Respiratory Syncytial Virus with Immunity to Infection in ChildrenViral Immunology, 1987
- Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton ratVirus Research, 1985
- Respiratory-Syncytial-Virus Infections, Reinfections and ImmunityNew England Journal of Medicine, 1979